论文部分内容阅读
目的:探讨诱导化疗在局限期小细胞肺癌治疗中的应用效果。方法:选取2012年7月至2016年7月高州市人民医院收治的70例局限期小细胞肺癌初治患者,按照随机数字表法,分为对照组和观察组,对照组采取单纯诱导化疗,观察组则在诱导化疗的基础上加上放化疗,采用依托泊苷、顺铂或者卡铂诱发化疗,对两组患者的有效率、生存率及不良反应进行分析。结果:对照组中,局限期小细胞肺癌患者经诱导化疗后,有效率达77.1%,患者1年生存率为71.4%,2年生存率为40.0%,所有患者平均生存期为15.2个月。观察组中,局限期小细胞肺癌患者经诱导化疗后,有效率达97.1%,患者1年的生存率为88.6%,2年的生存率为60.0%,所有患者平均生存期为22.4个月,组间比较,差异具有统计学意义(P<0.05)。两组患者经化疗后的不良反应主要表现为恶心、呕吐、乏力及骨髓抑制等,组间比较,差异无统计学意义(P>0.05)。结论:诱导化疗联合放化疗在局限期小细胞肺癌治疗中,效果较单纯诱导化疗好,更能够提高患者的生存期。
Objective: To investigate the effect of induction chemotherapy in the treatment of localized small cell lung cancer. Methods: From July 2012 to July 2016, 70 cases of newly diagnosed small cell lung cancer patients admitted to Gaozhou People’s Hospital were divided into control group and observation group according to random number table method. The control group was treated with simple induction chemotherapy, In the observation group, chemoradiotherapy was added on the basis of induction chemotherapy. Chemotherapy with etoposide, cisplatin or carboplatin was used to analyze the efficacy, survival rate and adverse reactions of the two groups. Results: In the control group, the effective rate was 77.1% after induction chemotherapy in patients with small cell lung cancer. The 1-year survival rate was 71.4%, the 2-year survival rate was 40.0%, and the average survival time was 15.2 months in all patients. In the observation group, the effective rate was 97.1% after the induction of chemotherapy in patients with localized small cell lung cancer, the one-year survival rate was 88.6%, the two-year survival rate was 60.0%, the average survival time was 22.4 months in all patients, The differences between the two groups were statistically significant (P <0.05). Adverse reactions after chemotherapy in the two groups were mainly nausea, vomiting, fatigue and bone marrow suppression. There was no significant difference between the two groups (P> 0.05). Conclusion: Induction chemotherapy combined with chemoradiotherapy in the treatment of localized small cell lung cancer, the effect is better than the simple induction chemotherapy, but also can improve the survival of patients.